OBJECTIVE: To assess the utility of glycated haemoglobin (HbA(1c)) level as an automated screening test for undiagnosed diabetes among hospitalised patients and to estimate the prevalence of undiagnosed diabetes among hospitalised patients. DESIGN, PARTICIPANTS AND SETTING: A 3-month prospective study of all adult patients admitted to a tertiary hospital. An HbA(1c) test was automatically undertaken on admission for all patients with a random plasma glucose (RPG) level ≥ 5.5 mmol/L. Demographic, admission and biochemical data were obtained from hospital databases. A subset of patients was recruited for an oral glucose tolerance test (OGTT) after discharge. MAIN OUTCOME MEASURES: Prevalence of undiagnosed diabetes (defined as HbA(1c) ≥ 6.5% in accordance with International Expert Committee and American Diabetes Association recommendations) and utility of automated HbA(1c) testing. RESULTS: The prevalence of undiagnosed diabetes was 11% (95% CI, 9.8%-12.4%) (262/2360) during the study period. A further 312 patients with known diabetes were admitted. The prevalence of undiagnosed diabetes was highest in the 65-74-years age group. The HbA(1c) test cost was $152 per new diagnosis of diabetes. Conservatively assuming an annual incidence of undiagnosed diabetes of 0.8%, the ongoing cost of testing hospitalised patients would be $2100 per new diagnosis of diabetes. RPG testing was not sensitive or specific in diagnosing diabetes. Patients were poorly compliant with the post-discharge OGTT (27% completion rate). CONCLUSIONS: HbA(1c) is a simple, inexpensive screening test that can be automated using existing clinical blood samples. Hospital screening for diabetes needs to be coupled with resources for management in the community.
OBJECTIVE: To assess the utility of glycated haemoglobin (HbA(1c)) level as an automated screening test for undiagnosed diabetes among hospitalised patients and to estimate the prevalence of undiagnosed diabetes among hospitalised patients. DESIGN, PARTICIPANTS AND SETTING: A 3-month prospective study of all adult patients admitted to a tertiary hospital. An HbA(1c) test was automatically undertaken on admission for all patients with a random plasma glucose (RPG) level ≥ 5.5 mmol/L. Demographic, admission and biochemical data were obtained from hospital databases. A subset of patients was recruited for an oral glucose tolerance test (OGTT) after discharge. MAIN OUTCOME MEASURES: Prevalence of undiagnosed diabetes (defined as HbA(1c) ≥ 6.5% in accordance with International Expert Committee and American Diabetes Association recommendations) and utility of automated HbA(1c) testing. RESULTS: The prevalence of undiagnosed diabetes was 11% (95% CI, 9.8%-12.4%) (262/2360) during the study period. A further 312 patients with known diabetes were admitted. The prevalence of undiagnosed diabetes was highest in the 65-74-years age group. The HbA(1c) test cost was $152 per new diagnosis of diabetes. Conservatively assuming an annual incidence of undiagnosed diabetes of 0.8%, the ongoing cost of testing hospitalised patients would be $2100 per new diagnosis of diabetes. RPG testing was not sensitive or specific in diagnosing diabetes. Patients were poorly compliant with the post-discharge OGTT (27% completion rate). CONCLUSIONS: HbA(1c) is a simple, inexpensive screening test that can be automated using existing clinical blood samples. Hospital screening for diabetes needs to be coupled with resources for management in the community.
Authors: Alessandra M Abdallah; Beatriz C A Alves; Flávia S Gehrke; Aleksandra V L Sant' Ana; Ligia A Azzalis; Virginia B C Junqueira; Fernando Adami; Edimar C Pereira; Fernando L A Fonseca Journal: J Clin Lab Anal Date: 2014-08-17 Impact factor: 2.352
Authors: Michał Wysocki; Maciej Walędziak; Hady Razak Hady; Mikołaj Czerniawski; Monika Proczko-Stepaniak; Michał Szymański; Natalia Dowgiałło-Wnukiewicz; Piotr Kozera; Jacek Szeliga; Michał Orłowski; Michał Pędziwiatr; Magdalena Szopa; Andrzej Budzyński; Piotr Major Journal: Obes Surg Date: 2019-09 Impact factor: 4.129
Authors: Elif I Ekinci; Alvin Kong; Leonid Churilov; Natalie Nanayakkara; Wei Ling Chiu; Priya Sumithran; Frida Djukiadmodjo; Erosha Premaratne; Elizabeth Owen-Jones; Graeme Kevin Hart; Raymond Robbins; Andrew Hardidge; Douglas Johnson; Scott T Baker; Jeffrey D Zajac Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240
Authors: Andrew J Farmer; Brian Shine; Laura C Armitage; Noel Murphy; Tim James; Nishan Guha; Rustam Rea Journal: Diabet Med Date: 2022-07-26 Impact factor: 4.213
Authors: Aaron J Simpson; Renata Krowka; Jennifer L Kerrigan; Emma K Southcott; J Dennis Wilson; Julia M Potter; Christopher J Nolan; Peter E Hickman Journal: BMJ Open Date: 2013-09-23 Impact factor: 2.692
Authors: Natalie Nanayakkara; Hang Nguyen; Leonid Churilov; Alvin Kong; Nyuk Pang; Graeme K Hart; Elizabeth Owen-Jones; Jennifer White; Jane Ross; Victoria Stevenson; Rinaldo Bellomo; Que Lam; Nicholas Crinis; Raymond Robbins; Doug Johnson; Scott T Baker; Jeffrey D Zajac; Elif I Ekinci Journal: BMJ Open Diabetes Res Care Date: 2015-09-07
Authors: Tien-Ming Hng; Amanda Hor; Sumathy Ravi; Xiaoqi Feng; Jaime Lin; Thomas Astell-Burt; David Chipps; Mark McLean; Glen Maberly Journal: BMJ Open Diabetes Res Care Date: 2016-06-03